The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compounds of formula (VIII) or Compound A or A-1. Thus, the present disclosure relates to such inhibitors including compounds of formula (VIII) and their use for management of cancer. In some aspects, the compound of formula (VIII) is Compound 1. The present disclosure also relates to methods of activating B cells or T cells via modulation of cap methyltransferases. The present disclosure also relates to methods of managing cancer with a molecule or biologic that generates unmethylated RNA. The generation of unmethylated RNA activates B cells and presents the RNA to B-cell receptor (BCR). The present disclosure therefore also relates to management of cancer by activating B cells and then adoptively transferring the B cells to exert an anticancer effect.

The present disclosure discloses a pharmaceutical molecule of Garcinol chemically complexed with cyclodextrins and the use of the complexed molecule in prevention and management of cardiac dysfunction induced by chemotherapy, drugs and/or other insults to the heart caused by lifestyle and disease conditions. The disclosure also relates to a method of extraction and purification of high yield of 95-99% pure Garcinol from Garcinia species and a method of chemically complexing Garcinol with cyclodextrins to improve its stability and bioavailability.